AI assistant
Niagen Bioscience, Inc. — Director's Dealing 2010
May 28, 2010
32418_dirs_2010-05-28_e010f5e0-33cb-43ff-b164-2cb96e6cb0ae.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: ChromaDex Corp. (CDXC.OB)
CIK: 0001386570
Period of Report: 2010-05-20
Reporting Person: FROST PHILLIP MD ET AL (10% Owner)
Reporting Person: Frost Gamma Investments Trust (10% Owner)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 6750002 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Warrants to Purchase Common Stock | $0.21 | 2013-05-20 | Common Stock (6750002) | Indirect |
Footnotes
F1: These securities are held by Frost Gamma Investments Trust, of which the Reporting Person is the trustee. The Reporting Person is one of two limited partners of Frost Gamma Limited Partnership ("FGLP"). The general partner of FGLP is Frost Gamma, Inc. ("FGI"), and the sole shareholder of FGI is Frost-Nevada Corporation, of which the Reporting Person is the sole shareholder.
F2: On May 20, 2010, Frost Gamma Investments Trust purchased 6,750,002 shares of common stock and was issued an immediately exercisable warrant to acquire an additional 6,750,002 shares of common stock exercisable at $0.21 per share. See also Footnote 1.